The role of the sphingolipid pathway in liver fibrosis: an emerging new potential target for novel therapies
The role of the sphingolipid pathway in liver fibrosis: an emerging new potential target for novel therapies
复制标题
DOI：
10.1152/ajpcell.00003.2020
复制
发表时间：
2020-05-01
影响因子：
5.5
通讯作者：
Ilan, Yaron
中科院分区：
文献类型：
--
作者：
Ishay, Yuval;Nachman, Dean;Ilan, Yaron
鞘脂 (SL) 是一类生物活性脂质，也是主要的细胞膜结构成分。 SL 包括三种主要化合物：神经酰胺 (Cer)、鞘氨醇 (Sp) 和 1-磷酸鞘氨醇 (S-1P)，所有这些化合物在细胞（尤其是肝脏）的生物学功能中都发挥着新的作用。他们正在对各种肝脏疾病进行研究，包括肝硬化和终末期肝病。在这篇综述中，我们概述了 SL 在肝脏病理学中的作用，并重点关注它们在肝纤维化发展中的潜在作用。我们描述了最近的证据，并表明 SL 是治疗肝病和纤维化的一个有前途的潜在治疗靶点。
Sphingolipids (SL) are a family of bioactive lipids and a major cellular membrane structural component. SLs include three main compounds: ceramide (Cer), sphingosine (Sp), and sphingosine-1-phosphate (S-1P), all of which have emerging roles in biological functions in cells, especially in the liver. They are under investigation in various liver diseases, including cirrhosis and end-stage liver disease. In this review, we provide an overview on the role of SLs in liver pathobiology and focus on their potential role in the development of hepatic fibrosis. We describe recent evidence and suggest SLs are a promising potential therapeutic target for the treatment of liver disease and fibrosis.